Our Synthetic vaccine technology and process know-how enable us to manufacture a wide range of conjugate vaccines. In addition to commonly used DT and TT carrier proteins, we have a number of carrier proteins including CRM197, which is produced by our proprietary high-yield bacterial strain and used in our MCV candidates. Our wide range of carrier proteins allows us to develop better multi-v

The mRNA technology has significant advantages in the R&D process and production cycles, including fast, scalable and uniform production. mRNA vaccines use antigen-encoding messenger RNA to induce humoral and cellular immunity through specific delivery systems that enable cells to take up and express the encoded antigen.It can act on intracellular and extracellular targets and express a variety of proteins without entering the nucleus and not requiring in vitro expression and purification. The development of mRNA vaccines only requires the replacement of the antigen sequence on a mature technology platform, which shows great advantages in dealing with public health emergency. CanSinoBIO’s COVID-19 mRNA vaccine and other prophylactic virus vaccine candidates are developed upon this platform.

Our culture media formulations are free from animal components, and our final product formulations are free from undesired phenol and preservatives. Such characteristics ensure consistent product quality and reduce potential risks of side effects.